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Abstract
Background Romiplostim, a thrombopoietin receptor
agonist (TPOra), is a second-line medical treatment option
for adults with chronic immune thrombocytopenia (ITP).
Clinical trials have shown that romiplostim increases
platelet counts, while reducing the risk of bleeding and, in
turn, the need for costly rescue medications.
Aims The objective of this study was to assess the cost
effectiveness of romiplostim in the treatment of adult ITP
in Ireland, in comparison with eltrombopag and the med-
ical standard of care (SoC).
Methods A lifetime treatment-sequence cost-utility Mar-
kov model with embedded decision tree was developed
from an Irish healthcare perspective to compare romiplo-
stim with eltrombopag and SoC. The model was driven by
platelet response (platelet count C50 9 109/L), which
determined effectiveness and progression along the treat-
ment pathway, need for rescue therapy (e.g. intravenous
immunoglobulin [IVIg] and steroids) and risk of bleeding.
Probability of response, mean treatment duration, average
time to initial response and utilities were derived from
clinical trials and other published evidence. Treatment
sequences and healthcare utilization practice were vali-
dated by Irish clinical experts. Costs were assessed in € for
2011 and included drug acquisition costs and costs asso-
ciated with monitoring patients and management of
bleeding, as available from published Irish reimbursement
lists and other relevant sources. Deterministic and proba-
bilistic sensitivity analyses were conducted.
Results Romiplostim treatment resulted in an average of
20.2 fewer administrations of rescue medication (IVIg or
intravenous steroids) over a patient lifetime than el-
trombopag, and 29.3 fewer rescue medication administra-
tions than SoC. Romiplostim was dominant, with cost
savings of €13,258 and €22,673 and gains of 0.76 and 1.17
quality-adjusted life-years (QALYs), compared with el-
trombopag and SoC, respectively. Romiplostim remained
cost effective throughout a variety of potential scenarios,
including short-term TPOra treatment duration (1 year).
One-way sensitivity analysis showed that the model was
most sensitive to variation in the cost of IVIg and use of
romiplostim and IVIg. Probabilistic sensitivity analysis
showed that romiplostim was likely to be cost effective in
over 90 % of cases compared with eltrombopag, and 96 %
compared with SoC at a willingness-to-pay threshold of
€30,000 per QALY.
Conclusions Use of romiplostim in the ITP treatment
pathway, compared with eltrombopag or SoC, is likely to
be cost effective in Ireland. Romiplostim improves clinical
outcomes by increasing platelet counts, reducing bleeding
events and the use of IVIg and steroids, resulting in both
cost savings and additional QALYs when compared with
current treatment practices.
Electronic supplementary material The online version of this
article (doi:10.1007/s40258-013-0044-y) contains supplementary
material, which is available to authorized users.
D. Lee (&)  A. Hirst  N. Brereton
BresMed, North Church House, 84 Queen Street,
Sheffield S1 2DW, UK
e-mail: dlee@bresmed.co.uk
P. Thornton
Beaumont Hospital, Beaumont, Dublin, Ireland
L. Kutikova
International Health Economics,
Amgen (Europe) GmbH, Zug, Switzerland
R. Deuson
Global Health Economics, Amgen Inc.,
Thousand Oaks, CA, USA
Appl Health Econ Health Policy (2013) 11:457–469
DOI 10.1007/s40258-013-0044-y
Key Points for Decision Makers
• Results of the cost-effectiveness analysis showed that
treatment with romiplostim was dominant, with cost
savings compared with both eltrombopag and stan-
dard of care, including rituximab, whether given
before or after rituximab in the Irish immune
thrombocytopenia treatment pathway.
• Savings are achieved through higher response rates,
driving a reduction in bleeding and the use of intra-
venous immunoglobulins and steroids.
1 Introduction
Primary immune thrombocytopenia (ITP; previously
termed idiopathic thrombocytopenic purpura), an acquired
immune-mediated disorder characterized by low peripheral
blood platelet counts (\100 9 109/L), is attributed to
increased platelet destruction and suboptimal platelet pro-
duction [1, 2]. In adults, ITP is typically a chronic condi-
tion ([12 months), with spontaneous remissions relatively
uncommon. A review of published literature, based mainly
on Western European data, found that the annual incidence
of ITP has been estimated at approximately 3–4 per
100,000 person-years in adults, while in children, estimates
ranged from 1.9 to 6.6 per 100,000 person-years [3]. While
precise epidemiology estimates for Ireland are lacking, an
incidence of 3.9 per 100,000 person-years has been
reported in the UK population-based General Practice
Research Database [4].
Chronic ITP can have serious clinical and economic
consequences, particularly linked to bleeding and impaired
quality of life (QOL). While many patients may present
with no symptoms or with minor bruising, others experi-
ence serious bleeding, including gastrointestinal bleeds,
extensive skin and mucosal bleeds and/or intracranial
haemorrhage [2]. Physical symptoms are a primary driver
of diminished QOL, and ITP patients score poorly on QOL
scales such as bother, psychological impact, fear, social
activity and work [5]. The economic burden of chronic ITP
has been examined in several studies [6]. An annual cost of
€26,581 (year 2007 values) per hospitalized patient has
been reported in France, with rescue medication accounting
for a substantial proportion of costs [6]. In the USA, ITP
drug therapy alone is estimated to account annually for
hundreds of millions of dollars [7], with mean annual per-
patient costs estimated at approximately $US28,000 (year
2000–2003 values) [8]. Studies that have examined the
costs associated with ITP consistently reveal that adults
with chronic ITP incur substantial per-patient medical
costs, primarily due to hospitalization required to manage
bleeding events, drug costs and costs of surgical interven-
tion [6–9], as well as having lower work productivity [7].
Active treatment is recommended for adult ITP patients
with platelet counts \30 9 109/L, or 30–50 9 109/L with
bleeding or risk of bleeding [1, 2]. First-line treatment
typically consists of a short course of glucocorticoids,
intravenous immunoglobulin G (IVIg) or anti-D (Rho)
immunoglobulin (anti-D), all of which target platelet
destruction [2]. These treatments generally provide rela-
tively short-lived platelet responses, with many patients
requiring repeated high doses of corticosteroids to maintain
a safe platelet count, at the risk of undesirable adverse
effects. Second-line options include surgical splenectomy
and various treatments based on immune suppression,
including off-label treatment with the anti-CD20 mono-
clonal antibody rituximab [2].
The thrombopoietin receptor agonists (TPOra) romi-
plostim and eltrombopag offer a different approach to
treatment of ITP, by increasing platelet production [1, 2].
In Europe, both TPOra are approved for use in splenec-
tomized adult patients who are refractory to other treat-
ments (e.g. corticosteroids, IVIg), and as second-line
treatment for those who are not candidates for splenectomy
[10, 11]. As noted in an International Consensus Report,
TPOra are the only ITP treatments with evidence of effi-
cacy and safety from randomized controlled trials [2].
Health technology assessment is becoming increasingly
required in the decision-making process in Ireland. We
therefore conducted a cost-effectiveness analysis of romi-
plostim for the treatment of chronic ITP in adult patients in
Ireland, from an Irish national payer perspective. In line
with the guidelines for economic evaluation in Ireland [12],
we considered only direct costs.
2 Methods
2.1 Patient Population and Model Structure
A treatment-sequence cost-utility model was developed to
assess the cost effectiveness of romiplostim within its
licensed indication for adult chronic ITP splenectomized
patients who are refractory to other treatments (e.g. corti-
costeroids, IVIg), and as second-line treatment for adult
non-splenectomized patients where surgery is contra-indi-
cated. The patient cohort that was modelled had similar
characteristics to patients from the romiplostim phase III
trials [13] and individuals participating in an Irish survey
[14]. A total of 50 % of patients were assumed to be
splenectomized and 50 % non-splenectomized. The med-
ian age was 52 years, and 65 % were women [13]. Three
treatment strategies were compared (Fig. 1):
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• romiplostim followed by current medical standard of
care (SoC);
• eltrombopag followed by SoC;
• SoC, including rituximab.
As rituximab use in ITP is off-label, the base-case
analyses assumed that TPOra were received before ritux-
imab in this pathway. However, as some patients might
receive romiplostim or eltrombopag after rituximab, this
treatment pathway was tested in sensitivity analysis. After
failing rituximab, patients moved on to azathioprine fol-
lowed by mycophenolate mofetil and finally cyclosporine.
The SoC pathway comprised rituximab (80 % of patients),
azathioprine (59 %), mycophenolate mofetil (37 %) and
cyclosporine (4 %).
A Markov model with embedded decision tree was
used with a 4-week cycle and a lifetime time horizon,
developed from the perspective of the Irish national
healthcare payer. A lifetime time horizon was deemed to
be the most appropriate, since adult ITP tends to be a
chronic disease; the 4-week cycle was used to match the
evaluation schedule used in the long-term extension
study [15]. Costs and outcomes were discounted at a 4 %
annual rate, as recommended by the Health Information
and Quality Authority (HIQA) in Ireland [12]. The
treatment sequence used in the model was based on the
findings of a 2008 survey of 169 UK clinicians [16], and
was updated by two Irish clinicians to be applicable for
Ireland [17].
The model was driven by platelet response (platelet
count C50 9 109/L), which determined effectiveness and
progression along the treatment pathway, need for rescue
therapy (IVIg and steroids) and risk of bleeding (Fig. 2).
Patients started on the first treatment in the pathway and
progressed to the next treatment if they did not have an
initial response or if they relapsed (platelet count \50 9
109/L) after responding. Each relapse on active treatment,
determined by platelet count \50 9 109/L, was followed
by a period of ‘watch and rescue’ before initiating the next
active treatment. Long-term treatment (keeping patients on
active therapy for as long as they had a continued response)
was modelled in the base case, and short-term treatment
(1 year only) with romiplostim and eltrombopag was tested
in a sensitivity analysis.
2.2 Clinical Inputs
Clinical efficacy data and utilities were derived from
clinical trials, an International Consensus Report [2] and
other published evidence.
The efficacy of each treatment within the model was
characterized by three parameters (Table 1):
• probability of initial platelet response (C50 9 109/L);
• average time to initial response;
• treatment duration after initial response (treatment
failure defined as platelets \50 9 109/L for 4 consec-
utive weeks) [i.e. durability of response].
Efficacy data for romiplostim were taken from the piv-
otal phase III trials reported by Kuter et al. [13] and a
subsequent long-term extension study [15]. The parallel,
multicentre, double-blind, placebo-controlled phase III
































Fig. 1 Model treatment pathways for adult immune thrombocytope-
nia (the proportions of patients represent patient treatment flow after
the failure of the previous treatment based on the findings of a 2008
survey of 169 UK clinicians [16] updated and validated to match Irish
practice [17]). SOC standard of care
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splenectomized patients. Patients were randomized to
receive romiplostim or placebo over a 24-week period,
with dosages adjusted according to weekly platelet
counts.
In order to facilitate a comparison with eltrombopag, an
odds ratio calculated by Bayesian meta-regression [18] was
used to derive relative response rates for eltrombopag
versus romiplostim (using romiplostim data from the
clinical studies mentioned above) [13], as shown in Online
Resource 1, Table 1A. The Bayesian meta-regression used
a logit model to indirectly compare the two TPOra,
accounting for differences in study effect, treatment effect
and the effect of splenectomy. In a sensitivity analysis, use
of the unadjusted response rate of 57 % for eltrombopag
[18] was also tested. The response rates for all other
treatments were obtained from published literature (see
Table 1). The time to response for each intervention was
assumed to be equal to the maximum response time cited in
the International Consensus Report (see Table 1) [2].
It was assumed that all patients who initiated therapy
received treatment throughout this time-to-response period,
with the exception of rituximab, which was given as a
single course. Treatment duration (time to platelets\50 9
109/L) was modelled for all treatments by retrospectively
fitting survival curves to available data. For romiplostim,
this was based on the reported number of patients who
were still on-treatment (or withdrew from the study for
reasons other than treatment failure) at each 12-week
interval in the 24-week trial and subsequent long-term,
open-label, extension study (using data for up to 288 weeks
and taking censoring into account) [13, 15]. Weibull, log-
Normal, log-logistic, exponential and Gompertz survival
curves were fitted to these data to allow extrapolation. The
mean duration of romiplostim treatment was estimated by
calculating the mean of the log-Normal function, which
was the best-fitting curve according to the Akaike Infor-
mation Criterion (AIC) (Table 2A, Figure 1A, Online
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Platelets ≥ 50 x 
109/L (W&R) 
Platelets < 50 x 
109/L Tn+1 or W&R 
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exhausted
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Dead
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Repeated every 4 week cycle
Dead
Fig. 2 Markov model with embedded decision tree overview (health states [platelets C50 9 109/L, platelets \50 9 109/L, dead] evaluated in
4-week cycles). GI gastrointestinal, W&R watch and rescue, Tn current treatment, Tn ? 1 next treatment in sequence
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mean treatment duration for eltrombopag, using the results
of the ongoing EXTEND (eltrombopag extended dosing)
study [19]. Based on the reported number of patients who
were still on-treatment or who dropped out for reasons
other than treatment failure, assuming a constant rate of
patient dropout and taking censoring after 2 years into
account, the log-Normal function was used to estimate the
mean treatment duration [20]. Again, the log-Normal
function was also the best-fitting curve based on the AIC
(Table 2A, Figure 1A, Online Resource 1). For all other
treatments, treatment duration was modelled by fitting
exponential curves through any available data points from
papers identified within the literature review that reported
the proportion of patients still responding over time.
While adverse events play a significant role in the
treatment of ITP, they were not included in the model due
to limited evidence available on the rates of events and
their impact on costs and QOL.
2.2.1 Bleeding Events and Rescue Medication Use
In the phase III romiplostim clinical trials, a proportion of
non-responders (i.e. patients with a platelet count \50 9
109/L) received rescue medication. It is noteworthy that
whilst a platelet count of C50 9 109/L was targeted in
these trials, no clinically significant bleeding occurred
when platelet counts were [20 9 109/L [21]. The proba-
bility of experiencing bleeding was based on clinical trial
data: patients who had a platelet count C50 9 109/L were
assumed to have a 12.64 % per-cycle probability of an
outpatient bleed (i.e. not requiring hospitalization) and
a 0.30 % per-cycle probability of an inpatient bleed
(requiring hospitalization) [21]. Corresponding per-cycle
probabilities for patients with a platelet count\50 9 109/L
were calculated as 40.77 and 3.69 %, respectively [21].
Among patients with an inpatient bleed, it was assumed
that 7 % experienced intracranial haemorrhage, 21 %
experienced a gastrointestinal bleed and 71 % experienced
another type of bleed [21]. Similarly, for each cycle, it was
assumed that 40 % of patients with a platelet count
\50 9 109/L would receive IVIg, while 8 % would
receive intravenous corticosteroids, for treatment of inpa-
tient or outpatient bleeding, or for bleeding prevention
[21]. As anti-D is not available in Europe, all patients who
received anti-D were assumed to receive IVIg (which has a
similar response rate to that of anti-D) [2].
2.2.2 Mortality
The model included combined mortality resulting from
serious bleeding and all-cause mortality. All-cause mor-
tality for patients was based on Irish life tables [22]. The
mortality risks associated with each type of bleed were
based on an analysis of the American Nationwide Inpatient
Sample (NIS) from 2003 to 2006 [9].
2.2.3 Utility
Utilities were taken from a time trade-off (TTO) survey
[23] conducted in the UK. The survey used TTO analysis to
directly measure the utility values for patients with ITP, as
perceived by 359 members of the general public, and
defined by five health states:
1. sufficient platelets (C50 9 109/L) with no outpatient
bleed;
2. sufficient platelets with an outpatient bleed;
3. low platelets (\50 9 109/L) with no outpatient bleed;
4. low platelets with an outpatient bleed;
5. intracranial haemorrhage.
An outpatient bleed refers to bleeding treated at a clinic,
health centre or general practice. For the remaining health
states used within the model (platelets \50 9 109/L and
gastrointestinal bleeding and platelets \50 9 109/L and
other bleeding), a utility value of 0.54 was used [24]. The
utilities were derived from cardiovascular patients who
experienced stroke, as ITP-specific data were not available.
EQ-5D utility values were available from the phase III
romiplostim clinical trials [13], with data from 117 patients
pooled across placebo and romiplostim arms, under the
conservative assumption that there is no treatment effect on
utility [25]. The TTO utility values [23] were used in the
base case (due to the larger sample size) and use of EQ-5D
values (n = 117) was investigated in sensitivity analysis
(Table 2).


















57 [18] 89.66 [19] 1
Rituximab 58 [39, 40] 18.87 [41–43] 2
Azathioprine 56 [44–46] 20.34 [47] 6
Mycophenolate
mofetil
50 [48–50] 5.68 [49] 2
Cyclosporine 57 [45, 51–53] 14.54 [53] 1
IVIg 81 [54–65] 1 [66] 0
IV steroids 46 [57, 67] 1 [66] 0
IV intravenous, IVIg intravenous immunoglobin
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2.3 Costs and Resource Use
Costs were assessed in €, year 2011 values, from the per-
spective of the Irish health service, exclusive of value
added tax (VAT), as per HIQA guidelines [12]. The model
considered drug acquisition and costs associated with
monitoring patients and management of bleeding. Resource
use and costs were derived from the International Con-
sensus Report [2], published Irish reimbursement lists,
individual summaries of product characteristics (SPCs)
[10, 11], real-life observational data [26] and other relevant
sources (Table 3). Healthcare utilization, such as frequency
of physician and nurse visits, was validated by Irish clini-
cians [17]. The cost of bleeds was estimated by taking a
weighted average of the relevant cost with and without
complications. The base-case model assumed that patients
received each treatment that they initiated for as long as
they continued to respond, with the exception of rituximab,
which was assumed to be given for a single course only.
Where 2011 values were not available, costs were inflated
using the health inflator derived from Central Statistics
Office Ireland [12].
The cost of IVIg was assumed to be €45 per g based on
Irish clinical practice [17]—this is lower than the list price





Platelets [50 9 109/L and no bleeding 0.863 0.790
Platelets [50 9 109/L and bleeding managed in outpatient care 0.734 0.730
Platelets \50 9 109/L and no bleeding 0.841 0.840
Platelets \50 9 109/L and bleeding managed in outpatient care 0.732 0.730
Platelets \50 9 109/L and intracranial haemorrhage 0.038 0.038
Platelets \50 9 109/L and GI bleeding [24] 0.540 0.540
Platelets \50 9 109/L and other bleeding [24] 0.540 0.540
GI gastrointestinal
Table 3 Healthcare utilization and costs












3 lg/kg = 1 9 250 lg
vial weeklya [13]
4 (1st 8 weeks);
1 ([8 weeks)
4 – €2,967.42 (1st 8 weeks);
€2,485.62 ([8 weeks)
Eltrombopag €2,043.58
(28 9 50 mg) [72]
55 mg/day [11] 4 (1st 8 weeks);
1 ([8 weeks)





4 9 375 mg/m2
4 (1st 8 weeks);
1 ([8 weeks)
– 4 €9,896
Azathioprine €36.75 (56 9 50 mg) 2 mg/kg/day 2 – – €377
Mycophenolatemofetil €164.84
(50 9 500 mg)
2 g/day 2 – – €714
Cyclosporine €151.11
(30 9 100 mg)
3 mg/kg/day 2 – – €682
Rescue medications
IVIg €45/g [17] 1 g/kg for 2 days 2 €7,776





GI bleed (inpatient) €2,913
Other inpatient bleed €2,913
Outpatient bleed €149
a Cost of full 250-lg vial was included in the analysis
GI gastrointestinal, IV intravenous, IVIg intravenous immunoglobin
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of €70.01 per g (based on a weighted average of the dif-
ferent available pack sizes) [27]. Uncertainty around the
price of IVIg was tested within the model (€37.60–52.40).
Although 70 % of patients self-administered romiplostim
in the open-label extension study [15], self-administration
was not included in the model.
2.4 Model Outputs
For each of the three treatments (i.e. romiplostim, el-
trombopag and SoC), the model calculated the following
over the patient’s lifetime:
• average number of administrations of rescue medica-
tion (IVIg or intravenous steroids);
• average number of bleeds;
• average number of hospitalizations.
Corresponding total costs, quality-adjusted life-years
(QALYs) and life-years (LYs) per patient, and the incre-
mental cost-effectiveness ratio (ICER) for romiplostim,
were calculated.
2.4.1 Sensitivity Analysis
Scenario analyses were conducted to test alternative sce-
narios in the model, addressing structural uncertainty.
These included the following:
• treatment duration of TPOra for 1 year instead of life-
long;
• placing TPOra after rituximab in the treatment
pathway;
• response rate of eltrombopag (impact of using the
unadjusted response rate taken directly from the clinical
trial vs. the adjusted response rate taken from the
indirect comparison);
• use of the EQ-5D as a source for utilities.
Deterministic sensitivity analysis was performed to
identify the parameters to which the model was most
sensitive, within their upper and lower bounds as defined
by 95 % confidence intervals where possible, or with
plausible variation around the base-case values. The
deterministic sensitivity analysis was based on incremental
net benefit, which was calculated as the incremental QA-
LYs multiplied by the willingness-to-pay threshold, minus
incremental costs. Probabilistic sensitivity analysis (PSA)
was conducted using 1,000 iterations to examine parameter
uncertainty over the entire model. The following parame-
ters were included in sensitivity analyses: response rates,
durations, bleeding and rescue medication use, utilities, the
proportion of patients using each SoC treatment, drug,
resource use and bleed costs, and patient demographics
(Table 3A, Online Resource 1).
3 Results
3.1 Base Case
The base-case (lifetime time horizon) model results
(Table 4) indicated that romiplostim treatment resulted in
an average of 20.2 fewer administrations of rescue medi-
cation (IVIg or intravenous steroids) over a patient lifetime
than eltrombopag and 29.3 fewer administrations than SoC.
The mean cost saving resulting from the reduction in res-
cue medications associated with romiplostim was €148,118
when compared with eltrombopag and €214,565 when
compared with SoC. Additionally, romiplostim was asso-
ciated with an average of 6.7 fewer bleeds and 1.7 fewer
hospitalizations than eltrombopag and 8.7 fewer bleeds and
2.4 fewer hospitalizations than SoC. The mean cost saving
resulting from the reduction in bleeds (including hospital-
izations) was, on average, €6,888 when compared with
eltrombopag and €10,296 when compared with SoC.
In total, the introduction of romiplostim into the
beginning of the current treatment sequence resulted, on
average, in a cost saving of €13,258 versus eltrombopag
and €22,673 versus SoC and was also associated with a
QALY gain of 0.76 versus eltrombopag and 1.17 versus SoC.
Romiplostim was therefore the dominant treatment, i.e. more
effective at a lower cost, and associated with cost savings and
QALY gains versus both eltrombopag and SoC.
3.2 Scenario Analyses
Several scenario analyses were conducted (Table 5). In the
short-term (1 year) TPOra treatment scenario, romiplostim
was associated with an average cost saving of €335 and a
QALY gain of 0.10 versus eltrombopag; hence, the use of
romiplostim remained dominant. When compared with
SoC, romiplostim was, on average, associated with an
additional cost of €895 and a QALY gain of 0.22. This
resulted in an ICER of €4,155, indicating that the use of
romiplostim remained cost effective.
The use of romiplostim after rituximab resulted in similar
cost savings and QALY gains compared with both SoC and
eltrombopag, the average cost saving increasing to€16,279 and
€27,022 compared with eltrombopag and SoC, respectively.
Additional scenario analysis tested the effect of using
the response rate of eltrombopag derived from the el-
trombopag clinical trial (instead of the response rate from
the Bayesian meta regression of romiplostim and el-
trombopag) [18]. Romiplostim remained dominant over
eltrombopag, despite using a higher eltrombopag response
rate (57 vs. 35 %) [Table 5].
Using the EQ-5D utility values resulted in a dominant
ICER for romiplostim compared with both eltrombopag
and SoC (Table 5).
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3.3 Deterministic and Probabilistic Sensitivity
Analyses
Figure 3 shows the results of the deterministic sensitivity
analysis, presented as the incremental net benefit consid-
ering a willingness-to-pay threshold of €30,000 per QALY.
The variables with the largest effect on the model were
similar when comparing romiplostim with either
eltrombopag or SoC. These were use of romiplostim, and
the cost and use of IVIg. It should be noted that these
findings are driven by the chosen ranges used in sensitivity
analyses. No variables had an impact on the cost-effec-
tiveness results at a threshold of €30,000 per QALY.
PSA showed that, in the majority of cases, treatment
with romiplostim was more cost effective than treatment
with either eltrombopag or SoC (Fig. 4). Romiplostim
dominated both eltrombopag and SoC in over 66 % of
cases, with a mean incremental net benefit of €35,823
Table 4 Base-case cost effectiveness of romiplostim compared with eltrombopag and standard of care
Romiplostim Eltrombopag SoC
Cost of rescue therapy €365,485 €537,617 €580,050
Cost of bleeds €17,126 €24,617 €27,422
Other costsa €216,092 €74,345 €13,904
Total costs €598,704 €611,962 €621,376
LY gained 14.70 13.97 13.57
QALYs gained 12.08 11.32 10.91
Romiplostim vs eltrombopag Romiplostim vs SoC
Incremental total costs – -€13,258 -€22,673
LYs gained – 0.73 1.13
QALYs gained – 0.76 1.17
ICER – Dominant Dominant
The figures used in the model include all relevant decimal places. The figures shown in this table are rounded and as a result, any calculations
made solely using the rounded figures may not provide an accurate result
a Other costs are active treatment costs: drug, physician and other utilization costs, and account for the length of time on therapy
ICER incremental cost-effectiveness ratio, LY life-year, QALY quality-adjusted life-year, SoC standard of care, Dominant indicates more
effective at lower cost
Table 5 Sensitivity analyses
Treatment arm Costs (€) QALYs Incremental costs (€) Incremental QALYs ICER
Short-term treatment duration with TPOra (1 year)
SoC 621,376 10.91 – –
Romiplostim 622,272 11.13 895 0.22 €4,155
Eltrombopag 622,607 11.03 335 -0.10 Dominated
Use of TPOra after rituximab treatment
Romiplostim 594,354 12.05 – – –
Eltrombopag 610,633 11.31 16,279 -0.74 Dominated
SoC 621,376 10.91 10,743 -0.40 Dominated
Use of unadjusted response rate for eltrombopag
Romiplostim 598,704 12.08 – – –
Eltrombopag 604,209 11.55 5,506 -0.54 Dominated
SoC 621,376 10.91 17,167 -0.63 Dominated
Use of EQ-5D utility values
Romiplostim 598,704 11.29 – – –
Eltrombopag 611,962 10.61 13,258 -0.68 Dominated
SoC 621,376 10.24 9,415 -0.37 Dominated
The figures used in the model include all relevant decimal places. The figures shown in this table are rounded and as a result, any calculations made solely using the
rounded figures may not provide an accurate result
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, SoC standard of care, TPOra thrombopoietin receptor agonist, Dominated indicates less
effective at higher cost
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versus eltrombopag and €56,869 versus SoC at a €30,000
per QALY threshold (Figure 2A, Online Resource 1).
There was a 90 % probability that romiplostim was cost
effective versus eltrombopag and a 96 % probability versus
SoC at a threshold of €30,000 per QALY (Figure 2A,
Online Resource 1).
4 Discussion
In phase III randomized, placebo-controlled clinical trials,
the majority of patients treated with romiplostim achieved
a platelet count of C50 9 109/L, while bleeding events
and the need for concurrent ITP therapies, including
0 20,000 40,000 60,000 80,000
Net Benefita
Lower Bound Parameter Upper Bound Parameter
Romiplostim usage: 1 (0.84-1.17) vials/week
IVIg cost: 45 (37.60-52.40)/g 
IVIg usage for patients with platelets ≥50 109/L: 0.4 (0.33-0.47) rate/cycle
Utility for platelets ≥50 109/L and no bleed: 0.863 (0.54-0.999) 
Romiplostim response duration: 140.86 (96.76-211.02) cycles
IV steroid use for patients with platelets <50 109/L: 0.08 (0.05-0.13) rate/cycle
Eltrombopag cost: 2043.58 (1719.45-2390.93)/pack
Utility for platelets <50 109/L and no bleed: 0.84 (0.42-1) 
Romiplostim response rate: 83 (70-93) % patients
Utility for platelets <50 109/L and OP bleed: 0.73 (0.37-0.97) 
IVIg daily admin cost: 300 (145.05-454.95) 
Eltrombopag response duration: 89.66 (69.86-116.72) cycles
Utility for platelets ≥50 109/L and OP bleed: 0.73 (0.37-0.97)
Eltrombopag response rate: 35 (31-40) % patients
Probability of inpatient bleed if platelets <50 109/L: 4 (1-7) % patients
Parameter: mean (95% CI or plausible range)
(a)
(b)
0 20,000 40,000 60,000 80,000 100,000
Net Benefita
Lower Bound Parameter Upper Bound Parameter
Parameter: mean (95% CI or plausible range)
Romiplostim usage: 1 (0.84-1.17) vials/week
IVIg cost: 45 (37.60-52.40)/g 
IVIg usage for patients with platelets <50 109/L: 0.4 (0.33-0.47) rate/cycle
Utility for platelets ≥50 109/L and no bleed: 0.86 (0.54-1) 
IV steroid use for patients with platelets <50 109/L: 0.08 (0.05-0.13) rate/cycle
Romiplostim response duration: 140.86 (96.76-211.02) cycles
Utility for platelets <50 109/L and no bleed: 0.841 (0.42-1) 
Utility for platelets <50 109/L and OP bleed: 0.732 (0.37-0.97) 
Romiplostim response rate: 83 (70-93) % patients
IVIg daily admin cost: 300 (145.05-454.95)
Utility for platelets ≥50 109/L and OP bleed: 0.734 (0.37-0.97) 
Probability of inpatient bleed if platelets <50 109/L: 4 (1-7) % patients
Azathioprine response duration: 20.34 (41.07- 3.52) cycles
IV steroids admin cost: 300 (145.05-454.95)/day
Fig. 3 Deterministic sensitivity analysis: a romiplostim vs. eltrombo-
pag, b romiplostim vs. standard of care (incremental net benefit is
based on the incremental QALYs multiplied by the willingness-to-pay
threshold, minus incremental costs. The central vertical line repre-
sents the base-case net benefit). CI confidence interval, IV intrave-
nous, IVIg intravenous immunoglobulin, OP outpatient
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corticosteroids and rescue treatments, were reduced
[13, 21, 28–30]. Long-term extension studies demonstrated
that platelet responses were sustained during prolonged
treatment periods of up to 5 years [15, 31, 32], with use of
glucocorticoids continuing to decrease [29]. The efficacy of
romiplostim was also demonstrated in a European obser-
vational study [26].
The model presented here showed that romiplostim
treatment was dominant, demonstrating better efficacy and
cost savings than both eltrombopag and SoC. Savings were
achieved through the higher response rates associated with
romiplostim, which led to a reduction in bleeding-related
episodes, including the use of rescue therapies. Romiplo-
stim remained dominant throughout a variety of potential
scenarios, including short-term (1 year) treatment with
TPOra, placement after rituximab, use of unadjusted
response rates for eltrombopag and the use of an alternative
source for utility values. The model was most sensitive to
assumptions surrounding the use of romiplostim, IVIg and
steroids, and the duration of response to romiplostim.
Nevertheless, romiplostim remained cost effective for all
model parameters. PSA showed that romiplostim was
likely to be cost effective in over 90 % of cases versus
eltrombopag and 96 % versus SoC at a willingness-to-pay
threshold of €30,000 per QALY.
The results of this cost-effectiveness analysis were
dependent on Irish treatment practice and the healthcare
system. Although the driver of the cost-effectiveness
results was the efficacy of romiplostim, transferability of
the results to other countries is subject to local costing and
healthcare systems. Romiplostim has been shown to be cost
effective compared with SoC and rituximab in other
countries. In Canada, a net cost impact model showed that
romiplostim is less expensive to prepare and administer
than IVIg and is associated with lower indirect costs from a
Canadian healthcare perspective [33]. Romiplostim was
also associated with lower cost per response over 6 months
when compared with rituximab from the French national
health system perspective [34] and when compared with
SoC in Spain [35].
Although the results of our analysis were robust to
multiple sensitivity analyses, several limitations need to be
recognized. Direct comparison could not be made between
romiplostim and eltrombopag due to a lack of head-to-head
clinical trial data. Hence, estimates of comparative efficacy
between the treatments were made using the indirect
comparison recommended by Cooper et al. [18]. Uncer-
tainty in this indirect comparison was assessed both in PSA
and through scenario analysis. When the unadjusted
response rates were used for both TPOra, romiplostim still
provided better efficacy over eltrombopag, and remained
cost saving. Additionally, clinical trial data for romiplostim
and eltrombopag were comparatively better quality, and
more recent, than the data for the other treatments (notably
rituximab). Moreover, in some cases, published data for
treatment pathways in Ireland were not available. Where
this was the case, clinician validation by two Irish clini-
cians was used. Data from the USA have been used in
estimating the mortality associated with ITP, as informa-
tion was not available for Ireland or the UK. However, the
impact of this parameter is limited, as one-way sensitivity
analysis showed that it was not a key model driver.
The model was built from the perspective of the national
healthcare payer in Ireland. The exclusion of a wider
societal perspective could have underestimated overall
costs associated with treatment. For romiplostim, because
of more frequent nurse appointments associated with sub-
cutaneous administration, indirect costs could include costs
for time taken off work, transport and other out-of-pocket
costs. However, the magnitude of these additional costs is
uncertain, especially as a large proportion of romiplostim
patients are able to administer romiplostim at home [15]. A
lifetime time horizon was deemed to be the most appro-
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4-week cycle was used to match the evaluation schedule
used in the long-term romiplostim extension study [15].
The base-case analyses assumed that TPOra were placed
before rituximab in the treatment pathway and used
according to their approved indication in Europe, i.e. adult
patients with chronic ITP failing splenectomy or as second-
line therapy in patients who have contraindications to
surgery [10, 11]. We assumed that patients would receive,
successively, azathioprine, mycophenolate mofetil and
cyclosporine, after TPOra and rituximab. We did not
include splenectomy in the model since it was assumed that
all patients who were candidates for this procedure would
already have been splenectomized.
It is important to note that the model was based on
conservative assumptions. We assumed that only one
course of rituximab was given, whereas the literature
suggests that repeated courses may be needed to sustain
response [2, 36]. The lack of inclusion of adverse events
also represents a conservative assumption when comparing
romiplostim with SoC. Available data indicate that romi-
plostim has a good safety profile [37], particularly in
comparison with currently available treatments that are
based on immunosuppression, which may predispose
patients to serious infections, a major cause of death in ITP
patients [38]. However, the exclusion of adverse effects
associated with romiplostim and other treatments may
underestimate the overall treatment costs reported in this
analysis.
5 Conclusions
In summary, the addition of romiplostim to the chronic ITP
treatment pathway, compared with eltrombopag or SoC
including rituximab, is likely to be cost effective in Ireland.
This was shown despite the generally conservative
assumptions applied in the model.
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